方法：对超高度近视患者20例40眼接受普通型ICL或散光型后房型人工晶状体(TICL)治疗，术前屈光度球镜-10.0～-18.0D，柱镜-0.25～-3.00D，等效球镜-15.32D，术后随访12mo，观察指标包括UCVA，BCVA、角膜地形图、主观和客观验光、角膜内皮细胞计数、眼压测量、裂隙灯检查。

结果：术后12mo，裸眼视力≥0.8者占80.0%(32眼)。30.0%(12眼)的术眼BCVA较术前提高1行，15.0%(6眼)的术眼BCVA较术前提高2行。术后12mo术眼屈光度在±0.50D者达70.0%(28眼)。术前患者平均眼压为16±2.8mmHg，术后6mo平均眼压为17±3.4mmHg，术前术后相比较差异无显著性(t=0.518，P=0.776)，术前患者角膜内皮细胞计数平均为2 823±243.6个/mm²，术后6mo平均为2 709±273.2个/mm²，术前术后比较无显著性差异(t=0.794，P=0.422)。未发生继发性青光眼、视网膜脱离及并发性白内障。

结论：ICL植入术矫正超高度近视具有良好的疗效和安全性， 远期效果有待进一步观察。

METHODS: ICL or Toric ICL(TICL)implantation was performed in 40 eyes of 20 patients with extreme high myopia. Spherical refraction of these patients was -10.0--18.0D and cylinder refraction was -0.25--3.00D. All the patients' equivalent spherical refraction was -15.32D. Uncorrected visual acuity(UCVA), best-corrected visual acuity(BCVA)slit-lamp examination, intraocular pressure(IOP), topography examination, amount of corneal endothelial cells was examined in these patients and follow-up was 12 months.

RESULTS:Twelve months after surgery, 32 eyes(80.0%)received UCVA better than 0.8. One line increased in eye chart of BCVA was 12 eyes(30.0%)and two lines were 6 eyes(15.0%)postoperatively. Refraction between +0.5D and -0.5D was 28 eyes(70.0%)after surgery. There was no significant difference of IOP between preoperation and postoperation(t=0.518, P=0.776). There was no significant difference of average amount of corneal endothelial cells before surgery(2 823±243.6/mm²)and 6 months after surgery(2 709±273.2/mm²). No other complications occurred during and after surgery.

CONCLUSION: For extreme high myopia, ICL implantation is safe and effective.